Compare 8x8 Inc (EGHT) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs 10X Genomics Inc — how do they compare? 8x8 Inc trades at $2.02 (market cap $309.09M), while 10X Genomics Inc trades at $57.21 (market cap $7.61B). The key difference: 10X Genomics Inc is far larger — about 24.6× 8x8 Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, 8x8 Inc nearer its low. Which is the better fit depends on your goals.
| EGHT | TXG | |
|---|---|---|
Market Cap | $309.09M | $7.61B |
Sector | Technology | Health |
52-Week High | $2.76 | $58.57 |
52-Week Low | $1.59 | $11.34 |
Enterprise Value | $576.02M | $7.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $1.995, down 10.94% in the past 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported record service revenue in Q1 2027, beating earnings estimates for the fourth consecutive quarter. Recent news highlights AI expansion and a new partner program aimed at customer growth.
The outlook is mixed: strong revenue growth and AI adoption offer upside, but high P/E of 71.33 and negative net income in 2025 pose risks. Analyst consensus is a buy with a $3.13 target, though debt levels and profitability challenges require monitoring for sustained investor confidence.
TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.
Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
